Antithrombotic therapy and survival in patients with malignant disease.
A broad range of studies suggest a two-way relationship between cancer and venous thromboembolism (VTE). Patients with cancer have consistently been shown to be at elevated risk for VTE; this risk is partly driven by an intrinsic hypercoagulable state elicited by the tumour itself. Conversely, thromboembolic events in patients without obvious risk factors are often the first clinical manifestation of an undiagnosed malignancy. The relationship between VTE and cancer is further supported by a number of trials and meta-analyses which, when taken together, strongly suggest that antithrombotic therapy can extend survival in patients with cancer by a mechanism that extends beyond its effect in preventing VTE. Moreover, accumulating evidence from in vitro and in vivo studies has shown that tumour growth, invasion, and metastasis are governed, in part, by elements of the coagulation system. On 22 May 2009, a group of health-care providers based in the United Kingdom met in London, England, to examine recent advances in cancer-associated thrombosis and its implications for UK clinical practice. As part of the discussion, attendees evaluated evidence for and against an effect of antithrombotic therapy on survival in cancer. This paper includes a summary of the data presented at the meeting and explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a consensus statement developed by the group.
Kakkar
A K
AK
Thrombosis Research Institute and Queen Mary University of London, Emmanuel Kaye Building Manresa Road, London SW3 6LR, UK. akkakkar@tri-london.ac.uk
Macbeth
F
F
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000401:mortality*; D054556:Venous Thromboembolism / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight
Cancer. 1994 Jul 1;74(1):38-45
8004580
Nat Clin Pract Oncol. 2005 Jul;2(7):356-63
16075795
Br J Surg. 1999 Jul;86(7):890-4
10417560
J Clin Invest. 1992 May;89(5):1469-77
1373740
J Thromb Haemost. 2007 Apr;5(4):729-37
17408406
Ann Intern Med. 1999 May 18;130(10):800-9
10366369
J Clin Oncol. 2005 Apr 1;23(10):2130-5
15699479
Oncogene. 2004 Jan 15;23(2):410-7
14724569
Am J Med. 1996 Mar;100(3):269-77
8629671
J Clin Invest. 1994 Sep;94(3):1320-7
7521887
Lancet Oncol. 2007 May;8(5):395-402
17466896
J Clin Oncol. 2004 May 15;22(10):1944-8
15143088
Int J Cancer. 2004 Dec 20;112(6):994-1002
15386437
Cancer. 1984 May 15;53(10):2046-52
6322957
J Clin Oncol. 1989 Aug;7(8):993-1002
2547030
Clin Cancer Res. 2003 Nov 1;9(14):5339-45
14614019
Mayo Clin Proc. 2006 Jun;81(6):758-67
16770976
Am J Physiol. 1997 Jul;273(1 Pt 1):C239-45
9252462
J Thromb Haemost. 2004 Aug;2(8):1266-71
15304029
Nat Med. 1996 Feb;2(2):209-15
8574967
BMC Cancer. 2009 Oct 06;9:355
19807917
N Engl J Med. 2000 Jun 29;342(26):1953-8
10874063
Br J Surg. 1995 Aug;82(8):1101-4
7648165
J Cell Biol. 1998 Mar 9;140(5):1241-53
9490735
Lancet. 1992 Jun 13;339(8807):1476
1351142
J Clin Oncol. 1997 Nov;15(11):3378-87
9363869